Welcome & introduction: Jesús San Miguel, Irene Ghobrial, Shaji Kumar, George Vassiliou, Kelly Bolton & Matthew Davids

Keynote talk 1: Measuring cancer evolutionarily dynamics for early detection: Trevor Graham

Plenary session 1: Advances in genomics, evolution, pathogenesis & therapeutic targets
Chairs: Leif Bergsagel & Mehmet Samur

• Genomic landscape of multiple myeloma and of its precursor conditions: Jean-Baptiste Alberge
• Genetically-driven immune microenvironment landscapes across myeloma subtypes: Romanos Sklavenitis-Pistofidis
• Evolution of clonal hematopoiesis to myeloid malignancy: Kristina Kirschner
• Insights into myeloid cancer prevention from the identification of novel germline risk variants for clonal haematopoiesis: Siddhartha Kar
• Role of EZH2 oncogenic mutation in lymphomagenesis: Ari Melnick

Panel discussion

Plenary session 2: Early detection, screening, risk stratification, and prevention
Chairs: Susan Slager & Rafael Fonseca

• Detection of pre-malignant clones at population scale using an in vivo methylation barcode: Jamie Blundell
• Immune remodeling by clonal hematopoiesis in adoptive cell therapy: Juan José Rodríguez
• Prognostication in CLL: Adalgisa Condoluci
• Beyond blood cancers: Updates on MCED and early detection and interception studies across solid tumors: Elisabeth O’Donnell
• Controlling obesity to prevent disease progression: Catherine Marinac

Panel discussion

Break

Breakout session 1

 

---

 

SMM/MGUS/MM track: Screening and risk stratification – building on 20-2-20
Chairs: Marta Chesi & Efstathios Kastritis

• Updates and follow-up from the ISTOP study: Sigrún Þorsteinsdóttir
• Risk stratification in SMM – the IMWG 2/20/20 model: Efstathios Kastritis
• Utilizing PANGEA for risk stratification of MGUS and SMM: Elias Mai
• CTCs and immunological tools for assessing risk of disease progression: Bruno Paiva
• Genomic and transcriptomic models to identify progression risk in MM: Jean-Baptiste Alberge

Panel discussion: Shaji Kumar, Kwee Yong, Jesús San-Miguel, Irene Ghobrial

 

---

 

CHIP/CCUS/myeloid track: Basic and translational studies in clonal hematopoiesis
Chairs: Ravindra Majeti & Pinkal Desai

• Somatic mutations in clonal hematopoiesis: Nuria Lopez-Bigas
• Mouse models of aberrant TCL1A expression in HSCs: Siddhartha Jaiswal
• The effect of DNMT3A mutations on haematopoietic stem cell differentiation, immune microenvironment and disease risk: Elisa Laurenti
• Mechanisms of clonal expansion and hyperinflammation in TET2-driven clonal hematopoiesis: Eirini Papapetrou

Panel discussion

 

---

 

MBL/CLL/lymphoma track: Biological states in MBL
Chairs: TBC & Francesco Angotzi

• Tonic BCR signaling / phosphoproteomics in MBL/CLL: TBC
• Dysregulation of BCR signaling and anergy directs epigenetic reprogramming in MBL: Christopher Oakes
• Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL: Livius Penter
• GETSeq to improve our understanding of MBL biology: Giovanni Tonon

Panel discussion

Welcome reception

Welcome to Day 2: Kelly Bolton & Shaji Kumar

Keynote talk 2: Clonal hematopoiesis, MBL and risk of hematological malignancies: Susan Slager

Plenary session 3: Clonal expansion: The concept and the context
Chairs: Siddhartha Jaiswal & Kylee Machlachlan

• Clone as concept: a (brief) history: David Steensma
• Prevention of clonal expansion of TP53-mutant CH upon exposure to genotoxic stressors: Ravindra Majeti
• Spontaneous and under treatment pressure clonal evolution patterns in MM: Mehmet Samur
• The immune microenvironment and disease progression in MGUS/SMM: TBC
• The role of CLECL1 in CLL clonal survival, expansion, and progression: Nicholas Chiorazzi

Panel discussion

Plenary session 4: Designing pre-cursor clinical trials
Chairs: Tait Shanafelt & Francesca Gay

• Identifying patients with CCUS for clinical trials: Central pathology review discordance: Lachelle Weeks
• Early intervention in low- and intermediate-risk SMM: Salomon Manier
• Role of PROs and QoL measurements in precursor trials: Hira Mian

Panel discussion

Break

Breakout session 2

 

---

 

SMM/MGUS/MM track: Evaluating different endpoints in SMM/MGUS trials
Chairs: Kwee Yong & Kylee Machlachlan

• Biochemical progression as an endpoint: Tarek Mouheddine
• Is MRD the best endpoint to incorporate in MGUS/SMM clinical trials?: Natalie Callander

Panel discussion: Tarek Mouheddine, Natalie Callander, Shaji Kumar, Kwee Yong, Jesús San-Miguel, Irene Ghobrial, Efstathios Kastritis, Omar Nadeem

 

---

 

CHIP/CCUS/myeloid track: Screening and prognosis in CHIP/CCUS
Chairs: Uma Borate & Juan José Rodríguez

• Population-level CBC-based pre-screening for high-risk CH: Lachelle Weeks
• DNA methylation as a prognostic biomarker for predicting DNMT3A and TET2 pre-disease progression: Alexander Bick
• Understanding factors of resilience in a longevity cohort and as they related to clonal hematopoiesis: Aditi Shastri

Panel discussion

 

---

 

CLL/MBL/lymphoma track: Novel biological insights and tools in MBL/CLL
Chairs: Andrew Rawstron & Anna Schuh

• Novel MRD assessment strategies in CLL: Anton Langerak
• The developmental trajectory of CLL derived from sibling stem cell donors of CLL patients: Hendrik Veelken
• Normal B cells in people with IGHV-unmutated MBL follow a different maturation pathway compared to people with IGHV-mutated MBL: Implications for disease origin: Gonzalo Blanco

Panel discussion: Andrew Rawstron, Anna Schuh, Aswin Sekar, Anton Langerak, Hendrik Veelken & Gonzalo Blanco

Lunch

Breakout session 3

 

---

 

SMM/MGUS/MM track: Latest clinical trials and evidence generation
Chairs: Elena Zamagni & Catherine Marinac

• Dietary intervention trial in MGUS/SMM – food for thought: Urvi Shah
• Current Phase II/ III trial in SMM: Jesús San Miguel
• Early rescue intervention with DPd in high-risk SMM: Jesús San Miguel
• Debate: Should high-risk SMM be treated with single-agent daratumumab or with curative-intent combination therapy?
  • Dara-monotherapy: Shaji Kumar
  • Curative-intent combination therapy: Nizar Bahlis

Panel discussion

 

---

 

CHIP/CCUS/myeloid track: Clinical studies in CHIP, CCUS and low-risk MDS
Chairs: George Vassiliou & Pinkal Desai

• Talk title TBC: Uma Borate
• Vitamin C efficacy in myeloid malignancies and precursor conditions requires functional TET2: A Phase 2 randomized, placebo-controlled trial: Kirsten Grønbæk
• IDH1/2 CH as a novel driver of autoimmune disease: Kelly Bolton
• Dietary intervention trial in CH – food for thought: Urvi Shah

Panel discussion

 

---

 

CLL/MBL/lymphoma track: Clinical investigations in precursor conditions
Chairs: Matthew Davids & Lydia Scarfò

• Early intervention strategies in early-stage CLL: Clemens Wendtner
• Vitamin D supplementation as early intervention in CLL: Tamar Tadmor
• Complementary interventions for early CLL: Lindsey Roeker
• Talk title TBC: Lydia Scarfò

Panel discussion

Break

Plenary session 5: Defining response criteria
Chairs: TBC & TBC

• Novel endpoints for MBL/early-stage asymptomatic CLL: Tait Shanafelt
• Non-hematologic endpoints for CH trials: Zhuoer Xie
• Defining new endpoints for SMM: Francesca Gay

Panel discussion

Plenary session 6: Latest from clinical studies I
Chairs: Sameer Parikh & David Steensma

• Incidence and outcomes of CD5- MBL: Sameer Parikh
• Using IMIDs/CeLMODs in the treatment of SMM: Nisha Joseph
• DFV890 and MAS825 for inflammatory marker reduction in patients with coronary heart disease and CHIP: Alexander Bick
• Beyond CHIP: CCRS predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma: Zhuoer Xie

Panel discussion

Day 2 wrap up
Matthew Davids

 

IBC 2026 dinner

Welcome to Day 3: George Vassiliou & Irene Ghobrial

 

Keynote talk 3: Talk title TBC: Inigo Martincorena

Plenary session 7: Latest from clinical studies II
Chairs: TBC & TBC

• Designing clinical trials for preemptive treatment – early results from the data-driven PreVent-ACaLL trial in CLL: Carsten Niemann
• Olutasidenib for low-risk MDS and CCUS: Kelly Chien
• Metformin in CCUS and low-risk MDS: Kirsten Grønbæk
• Evidence for using isatuximab-lenalidomide in high-risk SMM: TBC

Panel discussion

Plenary session 8: Latest from clinical studies III
Chairs: TBC & TBC

• Ivosidenib in IDH1-mutated CCUS: Kelly Bolton
• Impact of CH on therapy related myeloid neoplasms and therapeutic toxicity in patients undergoing targeted radiation therapy: Pinkal Desai
• Daratumumab-RVd in in HR-SMM and daratumumab in LR-SMM and HR-MGUS: Omar Nadeem
• Combining daratumumab and teclistamab for high-risk SMM: Ola Landgren

Panel discussion

Break

Plenary session 9: Can we predict treatment response or treatment resistance?
Chairs: TBC & TBC

• Genomic mechanisms of response and resistance: Brian Walker
• Spatial proteomics to identify resistance to therapy: TBC
• Immune predictors post-therapy in SMM: TBC

Panel discussion

Plenary session 10: Latest innovations
Chairs: Rafael Fonseca & Celine Vachon

• Digital pathology and AI in predicting progression: TBC
• GLP1/2 agonists for the prevention of disease progression: Elizabeth O’Donnell
• Talk title TBC: TBC 

Panel discussion

Plenary session 11: Stakeholder panel discussion: Screening pros and cons, how can we design correlative studies for RCTS, and what are the best measurements for patient QoL?
Chairs: George Vassiliou, TBC & TBC

Panellists: Irene Ghobrial, Zhuoer Xie, Matthew Davids, Kelly Bolton, Shaji Kumar, Rafael Fonseca, TBC, TBC & TBC

 

Plenary session 12: Breakout summaries, outcomes and initiatives

• MBL/CLL/lymphoma track: Matthew Davids & Aswin Sekar
• SMM/MGUS/MM track: Shaji Kumar & Irene Ghobrial
• CHIP/CCUS/MDS/AML track: George Vassiliou & Kelly Bolton

Meeting summary and close: Irene Ghobrial, Shaji Kumar, George Vassiliou, Kelly Bolton & Matthew Davids